The Valley Desk

Clinical trial reportBloodPublished

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

15 of 31 authors shown in byline order.

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Blood
Published
Subject terms
Humans; Multiple Myeloma; Neoplasm, Residual; Thalidomide; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Adult; Aged; Middle Aged; Female; Male
PubMed ID
40127397
PubMed Central ID
PMC13292241
Added to directory
Source checked

Report a correction or request removal